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The biological response to tumor necrosis factor (TNF) involves activation of MAP kinases. Here we report a
mechanism of MAP kinase activation by TNF that is mediated by the Rho GTPase family members Rac/Cdc42.
This signaling pathway requires Src-dependent activation of the guanosine nucleotide exchange factor Vav,
activation of Rac/Cdc42, and the engagement of the Rac/Cdc42 interaction site (CRIB motif) on mixed-lineage
protein kinases (MLKs). We show that this pathway is essential for full MAP kinase activation during the response
to TNF. Moreover, this MLK pathway contributes to inflammation in vivo.
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The tumor necrosis factor (TNF) signaling pathway is
established to be a target for the development of effective
strategies for the treatment of human inflammatory dis-
eases (Feldmann 2002). Knowledge of the mechanism of
TNF signaling is therefore important for the design of
novel therapeutic approaches. Biological responses to
TNF involve activation of signal transduction pathways,
including MAP kinases and NF-kB (Karin 2005).
TNF recruits TRADD, TRAF2, and RIP1 to the cytoplas-
mic domain of TNF receptor 1 (Micheau and Tschopp 2003).
This complex initiates signal transduction mediated by
NF-kB. Activation of the NF-kB pathway requires ubiqui-
tin-mediated activation of the protein kinase TAK1 (Skaug
et al. 2009). Studies of Tak1/murine cells confirm that
TAK1 is essential for TNF-induced activation of IkB kinase
b (IKKb) and the subsequent degradation of IkBa, a critical
step in NF-kB signaling (Sato et al. 2005; Shim et al. 2005).
The TAK1 protein kinase therefore plays a central role in
TNF-mediated activation of NF-kB.
TNF-stimulatedMAP kinase activation is alsomediated
by the TRADD/TRAF2/RIP1 complex that is recruited to
the cytoplasmic domain of TNF receptor 1 (Micheau and
Tschopp 2003). Severalmembers of theMAPkinase kinase
kinase (MAP3K) group (e.g., ASK1 [Ichijo et al. 1997;
Nishitoh et al. 1998; Tobiume et al. 2001], MEKK1 [Xia
et al. 2000], mixed-lineage protein kinase 3 [MLK3]
[Sathyanarayana et al. 2002; Chadee and Kyriakis 2004;
Brancho et al. 2005; Korchnak et al. 2009; Sondarva et al.
2009], TAK1 [Sato et al. 2005; Shim et al. 2005], and TPL2
[Das et al. 2005]) have been implicated in TNF-induced
MAP kinase activation. The relative contribution of these
MAP3Ks to TNF-stimulated MAP kinase activation is
unclear. The roles of individual MAP3Ks may reflect
differences between TNF-responsive cells and/or differ-
ences between separate MAP kinase pathways. These
MAP kinase pathways include the cJun N-terminal kinase
(JNK), p38 MAP kinase, and extracellular signal-regulated
kinases (ERKs). Each of these MAP kinases is activated by
different MAP kinase kinase (MAP2K) isoforms. Thus,
JNK activation requires MKK7 and cooperative signaling
by MKK4 (Tournier et al. 2001), TNF-stimulated activa-
tion of p38 MAP kinase requires both MKK3 and MKK6
(Brancho et al. 2003), and ERK activation is mediated by
MKK1 and MKK2 (Robinson and Cobb 1997). These
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pathways lead to ERK, JNK, and p38 MAP kinase activa-
tion by a dual phosphorylation (Thr and Tyr) mechanism.
It is established that TNF causes activation of Rho
family GTPase proteins—including Rac/Cdc42 (Wojciak-
Stothard et al. 1998; Kim et al. 1999; Puls et al. 1999;
Hanna et al. 2001)—that may contribute to actin cyto-
skeleton reorganization (Wojciak-Stothard et al. 1998)
and the production of reactive oxygen species (Kim et al.
2007; Yazdanpanah et al. 2009). The purpose of this study
was to examine whether the TNF-stimulated Rac/Cdc42
pathwaymight contribute toMAP kinase activation (Coso
et al. 1995; Minden et al. 1995). We report that TNF can
activate a PTPN1/Src/Vav pathway that causes MLK-
dependent activation of MAP kinases.
Results
Requirement of the Rac/Cdc42 interaction site
(CRIB motif) on MLK3 for TNF-stimulated
MAP kinase activation
Treatment of primary murine fibroblasts (MEFs) (Fig. 1A)
and bone marrow-derived macrophages (BMDMs) (Fig.
1B) with TNF causes rapid activation of Rac and Cdc42.
We examined whether this TNF-stimulated Rac/Cdc42
pathwaymight contribute toMAP kinase activation (Coso
et al. 1995; Minden et al. 1995) by binding to the Rac/
Cdc42 interaction site (CRIB motif) on MLK3 (Teramoto
et al. 1996). To test this hypothesis, we investigated the
effect of point mutations (Ile492 and Ser493 replaced with
Ala) that disrupt the CRIBmotif and prevent Rac/Cdc42-
dependent activation of MLK3 (Bock et al. 2000). Mice
with germline point mutations in the Mlk3 gene were
established (Mlk3DCRIB/DCRIBmice) and primary cultures
of MEFs were prepared (Fig. 1C–F). We found similar TNF-
stimulatedMAP kinase activation in control (Mlk3+/+) and
mutant (Mlk3DCRIB/DCRIB) MEFs (data not shown). This
observation may reflect a redundant role of MLK3 in TNF-
mediated signal transduction.
Gene expression analysis demonstrated that MEFs
primarily express MLK2 and MLK3 (Supplemental Fig.
S1). We therefore employedMlk2/mice (Supplemental
Fig. S2), Mlk3/ mice (Brancho et al. 2005), and com-
pound mutantMlk2/ Mlk3/ mice (Supplemental Fig.
S2) to prepare MEFs. Control studies demonstrated that
MLK deficiency did not alter cell morphology or pro-
liferation (Fig. 2). Deficiency of MLK2 or MLK3 caused
only minor changes in TNF-stimulated MAP kinase
activation (Supplemental Fig. S3), but TNF-stimulated
MAP kinase activation in Mlk2/ Mlk3/ MEFs was
markedly reduced (Fig. 1G). The reduced TNF-stimulated
MAP kinase activation detected in Mlk2/ Mlk3/
MEFs was not associated with altered TNF-stimulated
activation of IKKb or degradation of IkBa (Fig. 1G).
Thus, the MLK pathway (mediated by redundant func-
tions of MLK2 andMLK3) is required for maximal TNF-
stimulated MAP kinase activation, but is not required
for TNF-stimulated activation of the NFkB pathway.
This selective requirement of MLK2/3 for MAP kinase
activation was also observed in studies of Mlk2/
Mlk3/ BMDMs treated with TNF or lipopolysaccharide
(LPS) (Fig. 1H).
MLK2 and MLK3 have partially redundant functions
(Fig. 1G,H). We therefore re-examined the effect of the
MLK3 CRIB mutation in a MLK2-deficient genetic back-
ground. This analysis demonstrated that TNF-stimulated
MAP kinase activation inMlk2/Mlk3DCRIB/DCRIB MEFs
was markedly suppressed (Fig. 1I). In contrast, no differ-
ence in TNF-stimulated IkBa degradation was detected
between wild-type and Mlk2/ Mlk3DCRIB/DCRIB MEFs
(Fig. 1I). These data confirm that the MLK pathway con-
tributes to TNF-stimulated MAP kinase activation, but
not TNF-stimulated NF-kB activation.
To test whether Rac-mediated activation of MAP kinase
is mediated by the MLK pathway, we expressed constitu-
tively activated Rac in wild-type MEFs,Mlk2/ Mlk3/
MEFs, and Mlk2/ Mlk3DCRIB/DCRIB MEFs (Supplemental
Fig. S4). Activated Rac caused JNK activation in wild-type
MEFs, but did not cause JNK activation in MEFs with
MLK pathway defects. These data demonstrate that the
MLK pathway is an essential mediator of Rac signaling.
The low-level TNF-stimulated MAP kinase activa-
tion detected in Mlk2/ Mlk3/ MEFs and Mlk2/
Mlk3DCRIB/DCRIB MEFs (Fig. 1G–I) may be mediated by
TAK1. Indeed, TNF can cause partial MAP kinase activa-
tion in Tak1/ MEFs (Fig. 3A), and RNAi-mediated
knockdown of TAK1 inMlk2/Mlk3/MEFs strongly
reduced TNF-stimulatedMAPkinase activation (Fig. 3B–D).
Together, these data indicate that TNF-stimulated MAP
kinase activation ismediated by the coordinated activation
of at least two signaling pathways (MLK2/3 and TAK1).
Vav guanine nucleotide exchange factors
mediate TNF signaling
The suppression of TNF-stimulated MAP kinase activation
caused by mutation of the MLK3 CRIB motif (Fig. 1) in-
dicates that Rac/Cdc42 may mediate TNF-induced MAP
kinase activation. However, the mechanism that accounts
for TNF-stimulated Rac/Cdc42 activation is unclear. To
identify TNF-regulated guanine nucleotide exchange factors
(RhoGEFs), we isolated proteins that interact with a nucle-
otide-free form of Rac (Rac1Gly15Ala, a mimic of the guanine
nucleotide transition state) from control and TNF-treated
cells using affinity chromatography (Garcia-Mata et al.
2006). Vav was identified as a TNF-activated RhoGEF (Fig.
4A). In contrast, the RhoGEF isoforms GEFT and TIAM1
were not activated by TNF (Fig. 4A). To test whether Vav
contributes to TNF-stimulated Rac activation, we exam-
ined Rac activation in wild-type and Vav1/2/3-deficient
primary BMDMs (Fig. 4B). This analysis demonstrated that
Vav contributes toTNF-stimulated Rac activation (Fig. 4B).
TNF causes tyrosine phosphorylation
and activation of Vav
It is established that tyrosine phosphorylation represents
a major mechanism of Vav regulation (Swat and Fujikawa
2005). Indeed, TNF caused increased Vav tyrosine phos-
phorylation (Fig. 4C). Candidate tyrosine kinases that
might mediate this tyrosine phosphorylation include
Kant et al.
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members of the Src family (e.g., Src, Fyn, and Yes). We
found that TNF did not cause Vav tyrosine phosphoryla-
tion in Src/ Fyn/ Yes/ fibroblasts, but complemen-
tation analysis demonstrated that re-expression of Src was
sufficient to restore TNF-stimulated Vav tyrosine phos-
phorylation (Fig. 4D). Both Vav-deficient and Src/Fyn/Yes-
deficient cells exhibited defects in TNF-stimulated activa-
tion of MAP kinases (Fig. 4E,F). Together, these data
Figure 1. TNF causes activation of a Rac/Cdc42–MLK signal transduction pathway. (A,B) MEFs (A) or BMDMs (B) were treated
without or with 10 ng/mL TNFa. Activated (GTP-loaded) Rac/Cdc42 was isolated and quantitated by immunoblot analysis. The
amount of Rac/Cdc42 in cell lysates was measured by immunoblot analysis. (C) The structure of the Mlk3 genomic locus and the
targeting vector are illustrated. Homologous recombination causes the replacement of Mlk3 exon VII with a mutated form of exon VII
together with the insertion of a floxed NeoR cassette. The floxed NeoR cassette was excised using Cre recombinase. (D) The point
mutations in exon VII created by the targeting vector are illustrated. The nucleotide changes cause the elimination of an MslI
restriction site and the introduction of two amino acid substitutions (Ile492Ala and Ser493Ala) that disrupt the MLK3 CRIB domain.
(E) Genomic DNA from wild-type, Mlk3+/DCRIB, and Mlk3DCRIB/DCRIB mice was examined by PCR analysis to detect the wild-type and
mutant Mlk3 alleles. (F) Extracts prepared from wild-type (WT), Mlk3/, and Mlk3DCRIB/DCRIB MEFs were examined by immunoblot
analysis with antibodies to MLK3 and a-Tubulin. (G–I) Wild-type and Mlk2/ Mlk3/ MEFs (G), wild-type and Mlk2/ Mlk3/
BMDMs (H), or wild-type and Mlk2/ Mlk3DCRIB/ DCRIB MEFs (I) were treated without or with 10 ng/mLTNF or 100 ng/mL LPS. MAP
kinase and IKKb activation and the degradation of IkBa were examined by immunoblot analysis.
Role of MLK in TNF signaling
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demonstrate that a Src/Vav pathway contributes to TNF-
stimulated MAP kinase activation.
Requirement of PTPN1 for TNF-stimulated
Rac activation
Src family protein kinases have been previously impli-
cated in TNF-stimulatedMAP kinase activationmediated
by TRAF2-associated tyrosine phosphatases (van Vliet
et al. 2005). This pathway mediates TNF-stimulated
MAP kinase activation, but not TNF-stimulated NFkB
activation (van Vliet et al. 2005). The related tyrosine
phosphatases PTPN1 and PTPN2 can cause opposite
actions on Src family kinase activity by selectively dephos-
phorylating the inhibitory C-terminal site (PTPN1) or the
activating T-loop site (PTPN2) of tyrosine phosphorylation
(van Vliet et al. 2005). Increased PTPN1 and/or decreased
PTPN2 function may therefore contribute to TNF-stimu-
lated MAP kinase activation. We found that TNF caused
decreased tyrosine phosphorylation of the C-terminal site
of inhibitory tyrosine phosphorylation on Src (pY-527) in
BMDMs isolated from control mice, but not from Ptpn1/
mice (Fig. 5A). Moreover, TNF-stimulated Rac activation
(Fig. 5B) and MAP kinase activation (Fig. 5C) was sup-
pressed by PTPN1 deficiency. To confirm this observa-
tion, we examined the effect of selective small molecule
inhibitors of PTPN1 and PTPN2. We found that inhibition
of PTPN1 suppressed TNF-stimulated MAP kinase activa-
tion and that PTPN2 inhibition augmented TNF-stimulated
MAP kinase activation (Fig. 5D). These data demonstrate
that tyrosine phosphatases contribute to the regulation of
TNF-stimulated MAP kinase activation.
The MLK and TAK1 pathways mediate different TNF
biological responses
The results of this study demonstrate that full activation
of MAP kinases caused by TNF requires a Rac/Cdc42
signaling pathway that is mediated by Src-induced Vav
activation and engagement of MLK protein kinases. To
examine the contribution of this pathway to TNF signal-
ing, we compared the response of control and MLK-
deficient MEFs to treatment with TNF, including the
expression of inflammatory cytokines and cell death. We
found that TNF-treated Mlk2/ Mlk3/ MEFs secrete
markedly less interleukin 6 (IL6) than wild-type cells (Fig.
6A), consistent with reduced MAP kinase activation in
MLK-deficient cells (Fig. 1G,H). Previous studies have
established that the ERK, JNK, and p38 MAP kinase
pathways can contribute to Il6 gene expression (Tuyt
et al. 1999; Kim et al. 2004; Ventura et al. 2006), but
increased IL6 expression caused by the Vav pathway is
primarily mediated by JNK (Song et al. 1999). We found
that Mlk2/ Mlk3/ MEFs (like wild-type MEFs) acti-
vate the NF-kB survival pathway (Fig. 1G) and exhibit
resistance to the cytotoxic effects of TNF (Fig. 6B,C). In
contrast, Tak1/ cells were sensitive to TNF-mediated
cytotoxicity (Fig. 6B,C) and failed to activate the NF-kB
pathway (Fig. 3A). Together, these data demonstrate that
the MLK and TAK1 pathways mediate different TNF-
dependent cellular responses.
The MLK pathway contributes to inflammation in vivo
To test whether the MLK pathway can mediate inflam-
mation, we examined the effect of MLK deficiency on the
response of mice to endotoxin exposure. Treatment of
wild-type mice with LPS caused increased expression
of inflammatory cytokines (e.g., TNFa) and chemokines
(e.g., CCL3 and CCL5) in blood (Fig. 7A). These effects of
LPS were suppressed in MLK-deficient mice (Mlk2/
Mlk3/) and mice with MLK CRIB motif mutation
(Mlk2/ Mlk3DCRIB/DCRIB) (Fig. 7A). Control studies
using in vitro cultures of BMDMs confirmed that the
MLK pathway is required for LPS-stimulated cytokine
Figure 2. The effect of MLK2 and MLK3 de-
ficiency on growth. (A) The body mass of male
wild-type (WT) and Mlk2/ Mlk3/ mice was
measured at different time intervals (mean 6 SD;
n = 8). Statistically significant differences are
indicated. (*) P < 0.05. (B) Wild-type and Mlk2/
Mlk3/ MEFs were examined by phase-contrast
microscopy. (C) The proliferation of wild-type,
Mlk2/, Mlk3/, and Mlk2/ Mlk3/ MEFs
during culture for 7 d was examined by plating
2.5 3 104 MEFs in 11-mm wells using Dulbecco’s
modified Eagle’s medium supplemented with
10% fetal calf serum. Relative cell numbers were
measured by staining with crystal violet (mean 6
SD; n = 6). No significant differences between
wild-type and MLK-deficient MEFs were detected.
P > 0.05. (D) MEFs were incubated for 0 or 7 d
in Dulbecco’s modified Eagle’s medium supple-
mented with different amounts of fetal bovine
serum. Relative cell numbers were measured by
staining with crystal violet (mean 6 SD; n = 6).
No significant differences between wild-type and
MLK-deficient MEFs were detected. P > 0.05.
Kant et al.
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and chemokine expression (Fig. 7B). Together, these
data establish that the MLK pathway contributes to
inflammation.
Discussion
The biological response to TNF is mediated by the in-
tegrated actions of several signaling pathways. The NF-kB,
MAP kinase, and caspase pathways are key mediators of
the TNF response. TNF can also activate Rho family
GTPases, including Rac/Cdc42 (Wojciak-Stothard et al.
1998; Kim et al. 1999; Puls et al. 1999; Hanna et al. 2001).
Previous studies have established that Rac/Cdc42 may
contribute to the effects of TNF on actin cytoskeleton
reorganization (Wojciak-Stothard et al. 1998) and the
production of reactive oxygen species (Kim et al. 2007;
Yazdanpanah et al. 2009). Rac/Cdc42 therefore plays an
important role in the cellular response to TNF. Our study
demonstrates that TNF-stimulated Rac/Cdc42 activation
also contributes to MAP kinase regulation (Fig. 1).
The mechanism of TNF-stimulated Rac/Cdc42 activa-
tion requires Vav (Fig. 4B), a guanine nucleotide exchange
factor that is activated by tyrosine phosphorylation
(Crespo et al. 1997; Han et al. 1997) and can activate both
Rac and Cdc42 (Abe et al. 2000; Liu and Burridge 2000).
TNF causes tyrosine phosphorylation and activation
of Vav by Src family protein kinases (Fig. 4C,D) that
are activated by dephosphorylation on the inhibitory
C-terminal site of tyrosine phosphorylation (Fig. 5A). Src
activation requires the protein tyrosine phosphatase
PTPN1 (Fig. 5A). The related phosphatase PTPN2 can
oppose the activation of Src and functions to suppress
TNF-stimulated MAP kinase activation (van Vliet et al.
2005). The balance of PTPN1 and PTPN2 can therefore
determine the activation state of Src and, consequently,
the extent of Vav-mediated Rac activation. PTPN2 in-
teracts with TNF signaling complexes containing TRAF2
(van Vliet et al. 2005). The mechanism of TNF signaling
may therefore be mediated by sequestration of the in-
hibitory phosphatase PTPN2, by recruitment of the acti-
vating phosphatase PTPN1, or by coordinated regulation
of both phosphatases (activity and/or substrate access).
Further studies are required to define this mechanism and
to test whether Src activation might also require engage-
ment of the Src SH3 domain. Indeed, it is possible that the
Src-binding protein Sam68 (Fumagalli et al. 1994; Taylor
and Shalloway 1994), which acts as an adapter in TNF re-
ceptor signaling complexes (Ramakrishnan and Baltimore
2011), links TNF signaling to the Src pathway. Neverthe-
less, the data reported here demonstrate that TNF can
activate Rac by a PTPN1/Src/Vav pathway.
It is established that Rac/Cdc42 can cause MAP kinase
activation (Coso et al. 1995; Minden et al. 1995). The
effects of Rac/Cdc42 may be mediated by binding to the
CRIB motif on MLK3 (Teramoto et al. 1996). We report
that the functions of MLK3 are partially redundant with
the related protein kinase MLK2 in MEFs (Fig. 1G) and
macrophages (Fig. 1H). Compound gene disruption stud-
ies demonstrate that Mlk2/ Mlk3/MEFs and macro-
phages exhibit a severe defect in TNF-stimulated MAP
kinase activation (Fig. 1G,H). Moreover, the disrupted
MLK CRIB motif in primary cells isolated from Mlk2/
Mlk3DCRIB/DCRIBmice also causedmarkedly reduced TNF-
stimulated MAP kinase activation (Fig. 1I). These data
indicate that MLK protein kinases mediate the effects of
TNF-stimulated Rac/Cdc42 on MAP kinase activation.
The MLK protein kinases have been implicated in the
activation of the NF-kB pathway (Hehner et al. 2000).
However, we found no defects in TNF-stimulated IKKb
activation or IkBa degradation inMlk2/Mlk3/MEFs
(Fig. 1G). These data indicate that MLK protein kinases
are not involved in the TNF-stimulated NF-kB pathway.
Studies of Tak1/ MEFs demonstrated that TAK1 defi-
cieincy completely ablated the TNF-stimulated NF-kB
pathway, but caused only partial loss of TNF-stimulated
MAP kinase activation (Fig. 3A). Together, these data in-
dicate that TAK1 plays a key role in TNF-stimulated NF-kB
Figure 3. Residual MAP kinase activation in MLK-deficient
MEFs is mediated by TAK1. (A) Wild-type (WT) and Tak1/
MEFs were treated without or with TNFa (10 ng/mL). The
activation of MAP kinases and the degradation of IkBa was
examined by immunoblot analysis. (B,C)Mlk2/Mlk3/MEFs
were transfected with control (Scr) siRNA or Tak1 siRNA (72 h).
Transfection assays were performed using DharmaFECT 3 re-
agent with ON-TARGET plus Nontargeting Pool D-001810-10
for control or ON-TARGET plus SMART pool L-040718-00 for
Tak1 (MAP3K7) siRNA (Thermo Scientific). (B) The expression of
TAK1 and a-Tubulin was examined by immunoblot analysis. (C)
MAP kinase activation and the degradation of IkBa in response to
treatment with TNFa (10 ng/mL) were examined by immunoblot
analysis. (D) Mlk2/ Mlk3/ MEFs were transfected with
scrambled (Scr) siRNA or Tak1 siRNA (72 h). The MEFs were
treated without or with 10 ng/mL TNFa. Protein extracts were
examined by immunoblot analysis by probing with antibodies
to JNK1/2 and phospho-JNK. The siRNA for Tak1 were ON-
TARGET plus siRNA J-040718-07 (top panel) and J-040718-08
(bottom panel).
Role of MLK in TNF signaling
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activation and that both TAK1 and MLK protein kinases
contribute to TNF-stimulated MAP kinase activation.
The TAK1 and MLK pathways represent different
signaling mechanisms employed by TNF receptor 1. Both
of these pathways provide an opportunity for therapeutic
intervention that may be useful for the treatment of
human inflammatory diseases. However, the effects of
inhibition of these pathways are different because only
Figure 4. TNF-stimulated Rac activation is medi-
ated by Src and Vav. (A) Lysates prepared from
BMDMs treated without or with 10 ng/mL TNF (15
min) were incubated with immobilized Rac1G15A.
Bound proteins and the cell lysates were examined
by immunoblot analysis using antibodies to GEFT,
TIAM1, and Vav. (B) Wild-type (WT) and Vav1/
Vav2/ Vav3/ BMDMs were treated without or
with 10 ng/mL TNFa. Activated (GTP-loaded) Rac
was isolated and quantitated by immunoblot analy-
sis. The amount of Rac in cell lysates was measured
by immunoblot analysis. (C) Lysates prepared from
wild-type BMDMs treated without or with TNF were
examined by immunoprecipitation with a control
antibody (IgG) or with an antibody to Vav. The
immunoprecipitates were examined by immunoblot
analysis using antibodies to phosphotyrosine (pTyr)
and Vav. The cell lysates were examined by probing
with an antibody to a-Tubulin. (D) Src/ Fyn/
Yes/ fibroblasts complemented with Src (Control)
or without Src were treated without or with TNFa.
Lysates were examined by immunoprecipitation with
a control antibody (IgG) or with an antibody to Vav.
The immunoprecipitates were examined by immu-
noblot analysis using antibodies to pTyr. The cell
lysates were examined by probing with an antibody
to a-Tubulin. (E,F) Wild-type and Vav1/ Vav2/
Vav3/ BMDMs (E) or Control and Src/ Fyn/
Yes/ fibroblasts (F) were treated without or with 10
ng/mLTNF. MAP kinase activation was examined by
immunoblot analysis.
Figure 5. The protein tyrosine phosphatase PTPN1
contributes to TNF-stimulated MAP kinase activation.
(A) Lysates prepared from wild-type (WT) and Ptpn1/
BMDMs were treated without or with 10 ng/mL TNFa
and examined by immunoblot analysis using antibodies
to Src and pY527 Src. (B) Wild-type and Ptpn1/ BMDMs
were treated without or with 10 ng/mL TNF (15 min).
Activated (GTP-loaded) Rac1 was isolated and quanti-
tated by immunoblot analysis. The amount of Rac1 in
cell lysates was measured by immunoblot analysis. (C)
Wild-type and Ptpn1/ BMDMs were treated without
or with 10 ng/mL TNF. MAP kinase activation and
the degradation of IkBa was examined by immunoblot
analysis. (D) BMDMs were treated with solvent or with
drugs that selectively inhibit PTPN1 and PTPN2 (30
min). The cells were then treated with or without 10 ng/mL
TNFa (10min). Cell lysates were examined by immunoblot
analysis using antibodies to phospho-JNK, JNK, phospho-
p38, p38a, phospho-ERK, and ERK2.
Kant et al.
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TAK1 inhibition causes decreased NF-kB-mediated sur-
vival signaling (Fig. 6B,C). The reduced TNF-mediated
cytotoxicity caused by loss of MLK function, compared
with loss of TAK1 function, may be a beneficial property
of drugs that target MLK to inhibit TNF-stimulated in-
flammatory cytokine expression during disease progres-
sion in humans.
Materials and methods
Mice
C57BL/6J strain mice were obtained from The Jackson Labora-
tories. Mice withMlk3 (Brancho et al. 2005), Ptpn1 (Klaman et al.
2000), Tak1 (Shim et al. 2005), orVav1,Vav2, andVav3 (Fujikawa
et al. 2003) gene disruptions have been described previously.
Mice with germline mutations in exon VII of the Mlk3 gene
(Mlk3DCRIB) were constructed using homologous recombination
in LC1 embryonic stem (ES) cells (albino C57BL/6J genetic back-
ground). The targeting vector was constructed using a mouse
strain C57BL/6J genomic BAC clone containing the Mlk3 gene,
a floxedNeoR cassette, and a thymidine kinase cassette (Fig. 1C).
The ES cells were electroporated and selected with 200 mg/mL
G418 and 2 mM gangcyclovir. Correctly targeted ES cell clones
were injected into C57BL/6J blastocysts to create chimeric mice
that transmitted the mutated Mlk3 allele through the germline.
The floxed NeoR cassette was excised using Cre recombinase.
Mlk2/ gene disruption by homologous recombination using
129/SvJ strain ES cells was used to create a deletion (exon I to
exon VI) within theMlk2 gene (Supplemental Fig. S2). Correctly
targeted ES cell clones were employed to create chimeric mice
that transmitted the mutated Mlk2 allele through the germline
(D.S. Dorow, Peter MacCallum Cancer Institute). The Mlk2/
mice were backcrossed to the C57BL/6J strain (10 generations).
Themice were housed in a facility accredited by the American
Association for Laboratory Animal Care. All animal studies were
approved by the Institutional Animal Care and Use Committee
of the University of Massachusetts Medical School.
Genotype analysis
Wild-type (500-base-pair [bp]) and disrupted (600-bp) alleles of
Mlk2 were detected by PCR using the amplimers 59-CCTGG
TTCTCACTGGGACAACAG-39, 59-GTCACATCCACTTTCC
TGGGC-39, and 59-CGCCTTCTATCGCCTTCTTGAC-39. Wild-
type and disrupted alleles of Mlk3 (Brancho et al. 2005), Ptpn1
(Klaman et al. 2000),Tak1 (Shim et al. 2005), orVav1/2/3 (Fujikawa
et al. 2003) were detected by PCR analysis using genomic DNA
as the template. The Mlk3DCRIB allele (160 bp) was detected
by PCR amplification of genomic DNA using the amplimers
59-CCCAACCCCAAAATAAGC-39, and 59-CGGAGAACGCA
TCAGC-39; the corresponding wild-type allele (160 bp) was de-
tected using the amplimers 59-CCCAACCCCAAAATAAGC-39
and 59-CGGAGAACGCGCAGCC-39.
Cell culture
BMDMswere prepared (Das et al. 2009) and cultured inDulbecco’s
modified Eagle’s medium supplemented with 30% L929 super-
natant (source of M-CSF), 20% fetal bovine serum, 100 U/mL
penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine
(Invitrogen).
Src/ Fyn/ Yes/ fibroblasts complemented without and
with Src (Klinghoffer et al. 1999) were obtained from the American
Type Culture Collection (no. CRL2459 and no. CRL2498) and
were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 100 U/mL penicillin, 100
mg/mL streptomycin, and 2 mM L-glutamine (Invitrogen).
Embryonic day 13.5 (E13.5) primary MEFs were cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum, 100U/mLpenicillin, 100mg/mL streptomycin,
and 2mML-glutamine (Invitrogen). Retroviral transduction assays
(Lamb et al. 2003) were performed using the vectors pBABE-puro
and pBABE-Rac1Q61L-puro. Transfection assays were performed
Figure 6. The MLK pathway contributes to TNF-stimulated
signal transduction. (A) Wild-type (WT) and Mlk2/ Mlk3/
MEFs were treated with 10 ng/mL TNFa. The amount of IL6 in
the culture medium was measured by ELISA (mean6 SD; n = 6).
Statistically significant differences between wild-type andMlk2/
Mlk3/MEFs are indicated. (*) P < 0.05; (**) P < 0.01. (B,C) Wild-
type, Mlk2/ Mlk3/, and Tak1/ MEFs were treated with
10 ng/mL TNF (24 h). Cell death was examined by measuring
the presence of lactate dehydrogenase in the medium (B), and
cell viability was measured by staining with crystal violet (C).
The data presented are the mean 6 SD (n = 4). Statistically
significant differences between wild-type and Tak1/ MEFs are
indicated. (**) P < 0.01. No statistically significant differences
between wild-type and Mlk2/ Mlk3/ MEFs were detected.
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using DharmaFECT 3 reagent withON-TARGET plusNontarget-
ing Pool D-001810-10 for control or ON-TARGET plus SMART
pool L-040718-00 for Tak1 (MAP3K7) siRNA (Thermo Scientific).
Single siRNA for Tak1 were ON-TARGET plus siRNA J-040718-
07 and ON-TARGET plus siRNA J-040718-08. Cells were har-
vested at 72 h post-transfection. Proliferation assays and cell
viability assays were performed by staining cells with crystal
violet (Tournier et al. 2000). Cell death was examined by mea-
surement of lactate dehydrogenase release using a Cytotoxicity
Detection kit (Roche Applied Science).
The cells were treated with 10 ng/mLTNFa (R&D Systems) or
100 ng/mL LPS (Sigma). The cells were pretreated (30 min)
without or with an inhibitor of PTPN1 (200 nM) or PTPN2 (20
nM) (Sun et al. 2003; Zhang et al. 2009).
RNA analysis
The expression of mRNA was examined by quantitative PCR
analysis using a 7500 Fast Real-Time PCR machine (Applied
Biosystems). TaqMan assays were used to quantitate Mlk1
(Mm00616834_m1), Mlk2 (Mm01175535_m1), Mlk3
(Mm01233534_m1), Mlk4 (Mm00524049_m1), Tak1
(Mm00554514_m1), Tnfr1 (Mm01182929_m1), Tnfr2
(Mm00441889_m1), and Gapdh (4352339E-0904021) mRNA
(Applied Biosystems). Standard curves were constructed using
the threshold cycle (Ct) values for each template dilution plotted
as a function of the logarithm of the amount of input template.
The number of mRNA copies for each gene sample combination
was calculated using the slope of the standard curve. To obtain
a normalized abundance, copy numbers were corrected for the
amount of Gapdh mRNA in each sample.
Immunoblot analysis
Cell extracts were prepared using Triton lysis buffer (20 mMTris
at pH 7.4, 1% Triton X-100, 10% glycerol, 137 mMNaCl, 2 mM
EDTA, 25 mM b-glycerophosphate, 1 mM sodium orthovana-
date, 1 mM phenylmethylsulfonyl fluoride, 10 mg/mL aprotinin
and leupeptin). The lysates (50 mg of protein) were examined by
protein immunoblot analysis. Immunecomplexes were detected
by enhanced chemiluminescence (NEN). Primary antibodies were
obtained from Cell Signaling (Cdc42, phospho-IKKb, IKKb,
MLK3, phospho-ERK1/2, phospho-JNK1/2, p38a, phospho-p38,
Src, pY527-Src, Vav1/2/3, Rac1/2/3, and IkBa), BD Pharmingen
(JNK1/2), Millipore (Rac1, Vav, and phosphotyrosine), Santa Cruz
Biotechnologies (ERK2, TAK1, and TIAM1), Sigma (a-Tubulin),
and Proteintech Group (GEFT). The polyclonal antibody toMLK2
was purified from serum obtained from rabbits immunized with
a peptide that corresponds to MLK2 amino acids 898–911
(CISPPSRPDTPESPG-amide) conjugated to keyhole limpet hemo-
cyanin (Yenzym).
Immunoprecipitation
Cell extracts were prepared using lysis buffer (150 mMNaCl, 50
mM Tris at pH 8.0, 5 mM EDTA, 1% NP-40, 1 mM PMSF) and
incubated (5 h at 4°C) with 10 mg of control nonimmune rabbit
IgG (Santa Cruz Biotechnologies) or 10 mg of rabbit antibodies to
Vav (Millipore) and Vav1/2/3 (Cell Signaling). Immunecom-
plexes isolated using Protein G Sepharose were washed (five
times) with lysis buffer.
Cytokine and chemokine analysis
Cytokines in cell culture mediumwere measured by multiplexed
ELISA using a Luminex 200 machine (Millipore) and a serum
mouse cytokine kit (Millipore).
Rac/Cdc42 activation
Assays were performedwith the Rac/Cdc42 Activation Assay kit
using the manufacturer’s recommendations (Millipore). Cdc42
was detected by immunoblot analysis (Cell Signaling). Rac was
detected by immunoblot analysis using an antibody to Rac1
(Millipore) for studies of MEFs and an antibody to Rac1/2/3 (Cell
Signaling) for BMDM studies.
Analysis of RhoGEF proteins
TNF-activated RhoGEFs were identified by affinity chromatogra-
phy using a nucleotide-free transition state mimic of Rac1 (Garcia-
Mata et al. 2006). Cell extracts prepared using lysis buffer (150mM
NaCl, 50 mM Tris at pH 8.0, 5 mM EDTA, 1% NP-40, 1 mM
PMSF) were incubated with GST-Rac1G15A immobilized on
Figure 7. The MLK pathway contributes to LPS-
mediated inflammation. (A) Wild-type (WT) mice,Mlk2/
Mlk3/ mice, and Mlk2/ Mlk3DCRIB/DCRIB mice were
treated without and with 20 mg/kg LPS by intraperito-
neal injection (2 h). The amount of TNFa, CCL3/MIPa,
and CCL5/RANTES in the serum was measured by
ELISA (mean 6 SD; n = 8). Statistically significant
differences between wild-type and MLK-deficient mice
are indicated. (*) P < 0.05; (**) P < 0.01. (B) Primary
BMDMs were isolated from wild-type mice, Mlk2/
Mlk3/ mice, and Mlk2/ Mlk3DCRIB/DCRIB mice. The
BMDMs were treated without and with 100 ng/mL LPS
(24 h). The amount of TNFa, CCL3/MIPa, and CCL5/
RANTES in the culture mediumwas measured by ELISA
(mean 6 SD; n = 6). Statistically significant differences
between wild-type and MLK-deficient BMDMs are in-
dicated. (*) P < 0.05; (**) P < 0.01.
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GSH-Sepharose for 1 h at 4°C. The GSH-Sepharose was washed,
and bound proteins were examined by immunoblot analysis.
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